Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HardToFind who wrote (10055)	4/10/2018 9:08:35 PM
From: old 'n cranky	Read Replies (1) \| Respond to of 12873

Are you suggesting that because a Phase 1 could be done with 30-50 participants that they could run one for every indication because "we wouldn't mind getting some efficacy data on each of the would-be indications early on and relatively inexpensively"? I think I follow what you posted but I gather that the answer to the question that I posed is "No". "But I wouldn't hold up Phase I shingles testing to wait for pre-clinical data for the rest." If only you were in charge....but that's not the case. I'm lost. What do you expect them to do? Because I expect more of the same....an orchestrated stall.